Introduction: IBS-C and CC treatments include prescription medications, over-the-counter (OTC) laxatives, bulking agents, and stool softeners. This study aimed to characterize experiences and satisfaction with IBS-C and CC treatments among U.S. commercially insured patients. Methods: Patients aged ≥18 years with continuous medical and pharmacy benefit eligibility (from March 1, 2011 to February 28, 2013) were identified from the HealthCore integrated research database. IBS-C patients had ≥1 medical claim for IBS (ICD-9-CM 564.1x) and either ≥2 medical claims for constipation (ICD-9-CM 564.0x) or ≥1 medical claim for constipation plus ≥1 pharmacy claim for a constipationrelated prescription. CC patients had ≥2 medical claims for constipation occurring ≥90 days apart or ≥1 medical claim for constipation plus ≥1 constipation-related pharmacy claim ≥90 days apart. Consenting patients were administered modified Rome III criteria to confirm IBS-C/CC diagnoses. Only patients who met both claims and Rome criteria completed the full survey. Survey respondents were asked questions pertaining to their use of OTC and prescription medications to treat their IBS-C/CC in the last 6 months, including duration/frequency of use, satisfaction with medication’s ability to relieve their symptoms, predictability of bowel movements (BMs) associated with medication use, and reasons for medication discontinuation. Medications included polyethylene glycol (PEG), bulk laxatives (psyllium and wheat dextrin products), stimulant laxatives (bisacodyl and senna products), stool softeners, lubiprostone, lactulose, etc. Results: Of 178 survey respondents (53 IBS-C, 125 CC), mean (±SD) age of IBS-C patients was 40 (±15) years (85% female); mean (±SD) age of CC patients was 47 (±14) years (86% female). Overall, 86% of patients had taken ≥1 IBS-C/CC medication, and 70% had taken ≥2 medications in the past 6 months. Most frequently used medications were PEG (63%), stool softeners (55%), and bisacodyl products (40%). Over 65% were “not at all” to “moderately” satisfied with any medication’s ability to relieve their abdominal pain, bloating, or constipation. Over 75% expressed low confidence in having a BM at least once every other day and being able to predict BM timing after taking medication. For both IBS-C and CC patients, the most frequent reasons for medication discontinuation were inability to relieve abdominal pain and bloating and dissatisfaction with time to improvement of abdominal symptoms. Conclusion: A majority of patients reported taking ≥2 medications to manage their IBS-C/CC and being no more than moderately satisfied with any medication’s ability to provide symptom relief and produce reliable and predictable BMs. Results suggest there continue to be unmet needs for effective IBS-C/CC treatments. Disclosure - Qian Cai, Hiangkiat Tan, and Judith Stephenson: employees of Healthcore, Inc., which is a consultancy whose activities related to the project are funded by Forest Research Institute, and Ironwood Pharmaceuticals; Robyn Carson and Jessica Buono: employees of Forest Research Institute and own stock and/or stock options in Forest Laboratories, Inc.; William Spalding: employee of Ironwood Pharmaceuticals, Inc., and owns stock and/or stock options in Ironwood Pharmaceuticals; Jalpa Doshi: consultant to Forest Research Institute and Ironwood Pharmaceuticals. This research was supported by an industry grant from Forest Research Institute and Ironwood Pharmaceuticals.